AstraZeneca Suspends Coronavirus Vaccine Trials
Anglo-Swedish pharmaceutical company AstraZeneca has suspended testing of a coronavirus vaccine, which it is developing with the University of Oxford due to the illness of one of the volunteers, Bloomberg reports.
A man who took part in a clinical trial in the UK became ill with transverse myelitis ‒ an inflammation of the spinal cord that is usually caused by infections. AstraZeneca does not rule out that the disease could be a side effect of experimental vaccination. As a result, the trials were suspended to study data on the safety of the drug.
Due to the suspension of testing, AstraZeneca shares fell by 8% on the New York stock exchange. Later, the quotes were corrected, and the drop was 2.1%.
Earlier, Russian presidential spokesman Dmitry Peskov said that the Russian vaccine for the Sputnik V coronavirus is more reliable than the vaccine developed by the Anglo-Swedish company AstraZeneca. According to him, the Russian drug is based on human adenovirus, and the Anglo-Swedish vaccine is based on APE adenovirus.
The world's first vaccine against the coronavirus that developed in the Center of them. Gamalei was registered in Russia on August 11. It has passed two phases of clinical trials. The third phase should start next week. Mass production of the vaccine may begin in September 2020.